Testing SCTC21C for Systemic Lupus Erythematosus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new experimental drug called SCTC21C in people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. The trial aims to see if this drug can help reduce lupus symptoms and inflammation when added to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have been diagnosed with lupus for at least 3 months
- Currently taking at least one standard lupus medication (corticosteroid, antimalarial, or immunosuppressive drug)
- Have active lupus signs shown by blood tests and symptom scores
- Agree to use reliable birth control for 5 months after the last study drug dose (if able to become pregnant)
- Not have severe lupus affecting the brain, kidneys, or heart; or active infections, cancer, or other autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with lupus that has not responded well to standard treatments. It aims to reset the immune system to reduce lupus activity.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.